Evidence map›Paper›PMID 41536808›Full record

ArticleHemaSphere2026

Hussein Ghamlouch, Michaël Degaud, Veronique Della-Valle, Alexandre Eeckhoutte, Marine Armand, Amina Joudat, Camille Decaudin, Pilar M Dominguez, Wojciech Rosikiewicz, Patrycja Pawlikowska and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in HemaSphere, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hussein GhamlouchINSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy Villejuif France.ORCID https://orcid.org/0000-0002-2932-1081
Michaël DegaudINSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy Villejuif France.
Veronique Della-ValleINSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy Villejuif France.
Alexandre EeckhoutteINSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy Villejuif France.
Marine ArmandINSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy Villejuif France.
Amina JoudatINSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy Villejuif France.
Camille DecaudinINSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy Villejuif France.
Pilar M DominguezINSERM, Centre méditerranéen de médecine moléculaire (C3M) U1065 Université Côte d'Azur Nice 06204 France.
Wojciech RosikiewiczThe Jackson Laboratory for Genomic Medicine, Ten Discovery Drive Farmington Connecticut United States.
Patrycja PawlikowskaCNRS UMR9019, B cell and genome plasticity, Gustave Roussy Université Paris-Saclay Villejuif France.
Walaa DarwicheLaboratoire de cytogénétique et de génétique constitutionnelle, CHU Amiens-Picardie, UR4666, HEMATIM Université de Picardie Jules Verne France.
Enguerran MoulyINSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy Villejuif France.
Sheng LiDepartment of Cancer Biology, Norris Comprehensive Cancer Center, Keck School of Medicine University of Southern California Los Angeles California United States.
Ari M MelnickDepartment of Medicine Division of Hematology & Medical Oncology, Weill Cornell Medicine New York New York United States.
Said AoufouchiCNRS UMR9019, B cell and genome plasticity, Gustave Roussy Université Paris-Saclay Villejuif France.ORCID https://orcid.org/0000-0001-6547-2664
Olivier A BernardINSERM U1170; équipe labélisée Ligue Nationale Contre le Cancer, Gustave Roussy Villejuif France.ORCID https://orcid.org/0000-0002-0463-9747

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The germinal center (GC) reaction is essential for orchestrating humoral immunity by producing plasma cells (PCs) and memory B cells (MBCs). TET2, an α-ketoglutarate-dependent dioxygenase, plays a critical role in B-cell exit from the GC and in plasma cell differentiation. Moreover, TET2 functions as a tumor suppressor in diffuse large B-cell lymphoma (DLBCL), with mutations frequently observed in the ST2 DLBCL subgroup, which is marked by elevated NF-κB and PI3K signaling and predominant expression of IgG B-cell receptors (BCRs). We used a combination of

Identifiers

PMID41536808
PMCPMC12797087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.